On Tuesday, Schrodinger received an upgrade to its Relative Strength (RS) Rating, from 73 to 81.
This proprietary rating tracks technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the best stocks often have an RS Rating north of 80 as they launch their biggest climbs.
Hone Your Stock-Picking Skills By Focusing On These Factors
Schrodinger has climbed more than 5% past a 23.65 entry in a first-stage consolidation, meaning it's now out of a proper buy zone. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Schrodinger reported 0% earnings growth in its most recent report, while sales growth came in at -17%. Look for the next report on or around Feb. 26.
Schrodinger holds the No. 18 rank among its peers in the Medical-Research Equipment/Services industry group. Champions Oncology, Veracyte and Natera are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
